At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 320 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Semaglutide 0.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis
In Brief
A Phase 2 clinical trial evaluating Semaglutide and Placebo for Hepatobiliary Disorders and Non-alcoholic Steatohepatitis. Completed, enrolled 320 participants across 158 sites in 17 countries.
Detailed Summary
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Denmark, Finland, France, Greece, Japan, Netherlands, Puerto Rico, Russia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionFeb 2020
Study CompletionMar 2020
TodayJul 2026
First PostedNov 22, 2016
Enrollment StartNov 30, 2016
Primary CompletionFeb 13, 2020
Study CompletionMar 19, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.6 years ago
Interventions
Semaglutidedrug
Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
Placebodrug
Once daily administration subcutaneously ( s.c., under the skin)